1. Home
  2. Azioni
  3. Giappone
  4. Japan Exchange
  5. Solasia Pharma K.K.
  6. Notizie
  7. Altre lingue
    4597   JP3436500007

SOLASIA PHARMA K.K.

(4597)
  Rapporto
Tempo differito Japan Exchange  -  27/05 04:30:00
88.00 JPY   -1.12%
13/05Solasia Pharma K.K. fornisce una guida finanziaria consolidata per l'anno fiscale che termina il 31 dicembre 2022
CI
16/02L'indice giapponese si riprende mentre le tensioni geopolitiche si allentano; le azioni di Asahi guadagnano il 5% dopo i guadagni
MT
09/02Solasia Pharma K.K. fornisce una guida finanziaria consolidata per l'anno fiscale che termina il 31 dicembre 2022
CI
RiassuntoQuotazioniGraficiNotizieCalendarioSocietàFinanzaDerivati 
RiassuntoTutte le notizieAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su SOLASIA PHARMA K.K.
13/05Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending..
25/04SOLASIA PHARMA K K: Partner, Isofol announced start of study data analysis of SP-05 (arfo..
11/04HikariQ, Inc announced that it has received funding from Solasia Pharma K.K.
21/02SOLASIA PHARMA K K: Announcement of the matters to be resolved at the Ordinary General Me..
16/02Japan Index Rallies as Geopolitical Tensions Ease; Asahi's Stock Gains 5% Post Earnings
15/02Solasia Pharma to Raise Over $30 Million via Bonds and Warrants
14/02SOLASIA PHARMA K K: Announces Finance via Issuance of Unsecured Straight Bond and Warrant
09/02Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending..
2021Solasia Pharma Partner Receives Fast Track Designation from US FDA for Cancer Drug Deve..
2021SOLASIA PHARMA K K: Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin..
2021Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending Decembe..
2021Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 3..
2021Solasia Announces Revision to Full-Year Earnings Forecast
2021Solasia Pharma K.K. Revises Earnings Guidance for the Fiscal Year Ending December 31, 2..
2021Solasia Signs Drug Marketing Deal with Nippon Kayaku
2021SOLASIA PHARMA K K: Consolidated Financial Results for the First Six Months of the Fiscal..
2021SOLASIA PHARMA K K: Business Overview of Pipeline Products (Second Quarter of the Fiscal ..
2021Solasia Pharma K.K. Announces Consolidated Earnings Results for the Six Months Ended Ju..
2021Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending ..
2021SOLASIA PHARMA K K:  Solasia gibt die Einreichung eines neuen Zulassungsantrags für das K..
2021SOLASIA PHARMA K K: anuncia la presentación de la solicitud de registro para el antineopl..
2021SOLASIA PHARMA K K:  Solasia Announces Submission of New Drug Application for Anti-cancer..
2021Solasia Pharma K.K. Announces Submission of New Drug Application for Anti-cancer Drug D..
2021SOLASIA PHARMA K K: Announces Exercise Price Revisions Associated with Series 12 Warrants
2021SOLASIA PHARMA K K: Announces Submission of New Drug Application for Anti-cancer Drug DAR..
2021SOLASIA PHARMA K K: Announces episil was Recommended in Guidelines for Oral Mucositis Cau..
2021SOLASIA PHARMA K K: Announces Completion of Exercise of Series 11 Warrants
2021SOLASIA PHARMA K K: Consolidated Financial Results for the First Three Months of the Fisc..
2021SOLASIA PHARMA K K: Business Overview of Pipeline Products (First Quarter of the Fiscal Y..
2021Solasia Pharma K.K. Reports Consolidated Earnings Results for the Three Months Ended Ma..
2021Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending ..
2021SOLASIA PHARMA K K: Partner, Isofol Announces Global Phase III AGENT Study for arfolitixo..
2021Solasia’s Partner, Isofol Announces Global Phase III Agent Study for Arfolitixorin(SP-0..
2021SOLASIA PHARMA K K: Partner Isofol Receives Recommendation to Proceed with Arfolitixorin ..
2021SOLASIA PHARMA K K: Announced iDSMB Recommended to Complete Global Phase III AGENT Study ..
2021SOLASIA PHARMA K K: Announcement Concerning Partial Amendment to the Articles of Incorpor..
2021Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Year Ending Decembe..
2021Solasia Pharma K.K. Announces Consolidated and Non-Consolidated Earnings Results for th..
2020SOLASIA PHARMA K K: Results from the prematurely ended POLAR program with PledOx
2020SOLASIA PHARMA K K: Revises Full-Year Earnings Forecast for Fiscal Year Ending December
2020SOLASIA PHARMA K K: PledOx Fails to Meet Efficacy Endpoint in Phase III POLAR Program; Sh..
2020PLEDPHARMA: Results from the prematurely closed PledOx POLAR program
2020Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Year Ending December..
2020SOLASIA PHARMA K K: Swedish Partner Isofol Signs Up 440 Patients in Phase III Study for C..
2020Solasia Pharma K.K. Reports Consolidated Earnings Results for the Nine Months Ended Sep..
2020SOLASIA PHARMA K K: Announces episil oral liquid Launched in South Korea
2020Solasia Pharma K.K. Announces episil Oral Liquid Launched in South Korea
2020SOLASIA PHARMA K K: Isofol and Solasia Enter License Agreement to Develop and Commerciali..
2020SOLASIA PHARMA K K: Supplementary materials for Aug 13, 2020 announcement
2020SOLASIA PHARMA K K: Announces Finance via issuance of Unsecured Straight Bond and Warrant
2020ISOFOL MEDICAL PUBL: Invitation to a conference call and webcast by Isofol in connection ..
2020ISOFOL MEDICAL PUBL: enters licensing agreement with Solasia to develop and commercialize..
2020Isofol Medical AB Enters into Licensing Agreement with Solasia to Develop and Commercia..
2020SOLASIA PHARMA K K: Business Overview of Pipeline Products (Second Quarter of the Fiscal ..
2020SOLASIA PHARMA K K: Consolidated Financial Results for the Six Months of the Fiscal Year ..
2020Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Year Ending Decembe..
2020Solasia Pharma K.K. Reports Consolidated Earnings Results for the Six Months Ended June..
2020SOLASIA PHARMA K K: verkündet positive Ergebnisse von DARINAPARSIN in zentraler Phase-2-S..
2020SOLASIA PHARMA K K: Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study f..
2020Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Periphe..
2020Solasia Pharma K.K. Announces Consolidated Earnings Results for the First Quarter Ended..
2020Solasia Pharma K.K. Announces Update on SP-04
2020Solasia Pharma K.K. Proposes Retirement of Directors
2020Solasia Pharma K.K. Announces Consolidated and Non-Consolidated Earnings Results for th..
2019Solasia Pharma K.K. and Editforce Inc. Enter into Joint R&D Agreement
2019Solasia Pharma K.K. announced that it has received ¥1.709924 billion in funding from Ma..
2019SOLASIA PHARMA KK: PledPharma's global Phase III study POLAR-A is fully recruited
2019SOLASIA PHARMA KK: kündigt Lizenz- und Kapitalallianz für SP-04 (PledOx®) mit Maruho an
2019SOLASIA PHARMA KK: Announces License and Capital Alliance for SP-04 (PledOx®) with Maruho
2019Solasia Pharma K.K. Announces License and Capital Alliance for SP-04 (PledOx®) with Mar..
2019Solasia Pharma K.K. announced that it expects to receive ¥1.709924 billion in funding f..
2019Solasia Pharma K.K. Reports Consolidated Earnings Results for the Nine Months Ended Sep..
2019SOLASIA PHARMA KK: Announces Approval of episil® oral liquid in South Korea
2019Solasia Pharma K.K. Announces Development Strategy for Expanded Indication of PledOx an..
2019SOLASIA PHARMA KK: gibt bekannt, dass bei der Patientenregistrierung für die Phase-2-Schl..
1  2Pross.